As we approach 2026,late-stage programs across key therapeutic areas are poised to reshape treatment paradigms. Driven by novel mechanisms, first-in-class targets and more convenient administration ...
The last time I spoke about Prothena Corporation plc (PRTA), it was in a Seeking Alpha article entitled "Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place." I went ...
The new examination of global early-stage biopharmaceutical development programs from 2015 through 2025 found that while the United States remains the single largest originator of early-stage drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results